Immunic Q3FY26 Results: EPS of $(0.99) misses estimate, loss narrows 25% YoY
Immunic Inc reported a Q3FY26 EPS loss of $(0.99), missing estimates by $(0.03) but narrowing losses by 25% YoY. Operating expenses rose 65% to $42.3M, with R&D and G&A costs increasing. The company expects Phase 3 ENSURE trial data in December 2026 and has $132M in cash to fund operations into late 2027.
How this was made

The 30-second read
Why it matters
The earnings miss by $0.03 per share may trigger short‑term price pressure, but the cash position and upcoming data could create volatility ahead of the December readout.
Market read
First‑report earnings release for a micro‑cap biotech; modest trading relevance with potential volatility around upcoming trial data.
What to watch
The significant share dilution from the February private placement masks the loss expansion; analysts may under‑weight the impact of the larger cash balance.
Background
Immunic Inc., a clinical‑stage biotech developing vidofludimus calcium for multiple sclerosis, released its Q3 FY2026 results, highlighting a narrowed loss per share and upcoming Phase‑3 trial readouts.
Market effects
Biotech sector may see modest pressure as a micro‑cap reports a loss miss but narrows EPS; peers could be impacted by upcoming Phase‑3 data expectations.
Limited to U.S. and Canadian biotech investors; no broader regional effect.
Low global relevance; primarily relevant to niche biotech investors.
Counterpoint
Despite the EPS miss, the expanded cash runway and upcoming pivotal trial data could support a short‑term bounce if investors focus on cash sufficiency.
Key entities
- companyImmunic Inc.
Biotech firm reporting Q3 FY2026 results and Phase‑3 trial timeline.


